Immunovant Stock Target Price and Analyst Consensus
| IMVT Stock | USD 18.19 1.25 6.43% |
The current analyst and expert consensus on Immunovant is Strong Buy, with 10 strong buy opinions. The current projected Immunovant target price consensus is 50.25 with 14 analyst opinions. Check out Macroaxis Advice on Immunovant to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.The most common way Immunovant analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Immunovant executives and customers to further validate their buy or sell advice. Immunovant buy-or-sell recommendation module provides average expert sentiment on the projected Immunovant target price to derive its highest and lowest estimates based on projected price volatility of 3.3957.
Lowest Forecast 45.73 | Highest Forecast 55.78 | Target Price 50.25 |
Immunovant |
It's important to approach Immunovant's target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Immunovant Target Price Consensus
Immunovant target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Immunovant's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 14 | Strong Buy |
Most Immunovant analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Immunovant stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Immunovant, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationImmunovant Target Price Projection
Immunovant's current and average target prices are 18.19 and 50.25, respectively. The current price of Immunovant is the price at which Immunovant is currently trading. On the other hand, Immunovant's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Immunovant Target Price
Immunovant Analyst Ratings
Immunovant's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Immunovant stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Immunovant's financials, market performance, and future outlook by experienced professionals. Immunovant's historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Immunovant price targets
Immunovant's stock target price is an estimate of its future price, usually made by analysts. Using Immunovant's target price to determine if it is a suitable investment can be done through the following steps:- Look at Immunovant's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Immunovant's stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Immunovant Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Immunovant is a key component of Immunovant valuation and have some predictive power on the future returns of a Immunovant.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Immunovant's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Cancer Fighters Invested over 90 shares | |
 | Air Invested over 400 shares | |
 | Macroaxis Index Invested over 200 shares | |
 | Compulsion Invested over 20 shares | |
 | Precious Metals Invested over 100 shares | |
 | Momentum Invested over 300 shares | |
 | Cash Cows Invested few shares | |
 | Warren Buffett Holdings Invested few shares | |
 | Automobiles and Trucks Invested over 300 shares | |
 | Dividend Beast Invested over 60 shares |
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.